Anti‑proliferative effects of <em>Drynaria fortunei</em> in a model for triple negative breast cancer

Telang,Nitin T.; Nair,Hareesh B.; Wong,George Y.C.

doi:10.3892/ol.2024.14837

Anti‑proliferative effects of Drynaria fortunei in a model for triple negative breast cancer

Authors:
- Nitin T. Telang
- Hareesh B. Nair
- George Y.C. Wong
View Affiliations

Affiliations: Cancer Prevention Research Program, Palindrome Liaisons Consultants, Montvale, NJ 07645‑1559, USA, University of Texas Health Science Center, San Antonio, TX 78229, USA, American Foundation for Chinese Medicine, New York, NY 10001, USA
Published online on: December 6, 2024 https://doi.org/10.3892/ol.2024.14837
Article Number: 91
Copyright: © Telang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple negative breast cancer (TNBC) is characterized by the absence of hormones and growth factor receptors. It is typically responsive to anthracycline/taxol‑based conventional chemotherapy. However, major therapeutic limitations include systemic toxicity and acquired resistance to chemotherapeutics. To combat this, nutritional herbs from traditional Chinese medicine (TCM) with limited reported toxicity may represent treatment alternatives for TNBC. Such herbs can effectively target multiple signaling pathways in numerous breast cancer models. The efficacy of various nutritional herbs in a cellular model of TNBC is associated with the downregulation of retinoblastoma (RB) signaling through the cyclin D‑CDK4/6‑RB axis. Therefore, the present study was designed to examine the effects of Drynaria fortunei (DF) in the same cellular model of TNBC to identify potential mechanistic leads for its efficacy. DF is a nutritional herb that represents a common component of herbal formulations used in TCM. The estrogen receptor‑negative, progesterone receptor‑negative and human epidermal growth factor receptor‑2‑negative MDA‑MB‑231 human breast carcinoma‑derived cell line was used as the cellular model for TNBC in the present study. Non‑fractionated aqueous extract from the bark of DF represented the test agent. Quantitative end‑point biomarkers for the efficacy of DF assessed in the present study included cell cycle progression, RB signaling and caspase 3/7 activity. Treatment with DF at cytostatic concentration induced S phase cell cycle arrest and inhibited RB signaling as evidenced by the downregulated expression of cyclin E, CDK2, E2F1 and RB phosphorylation. DF treatment increased pro‑apoptotic caspase 3/7 activity which was inhibited by the pan‑caspase inhibitor Z‑VAD‑FMK. DF treatment also exhibited increased expression of cleaved ADP‑ribose) polymerase‑1. These data identify potential mechanistic leads for anti‑proliferative and pro‑apoptotic effects of DF in the present TNBC model. The present experiments validated a mechanism‑driven experimental approach to identify efficacious nutritional herbs and/or their bioactive constituents as treatment alternatives for TNBC.

View Figures

View References

1	American Cancer Society: Cancer Facts & Figures 2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdfJune 7–2024
2	Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP and Weeks JC: Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 118:5463–5472. 2012. View Article : Google Scholar : PubMed/NCBI
3	Velloso FJ, Bianco FJR, Farias JO, Torres NE, Ferruzo PY, Anschau V, Jessus-Farreira HC, Chng TH, Sogayar MC, Zerbini LF and Correa RG: The crossroads of breast cancer progression: Insights into the modulation of major signaling pathways. Onco Targets Ther. 10:5491–5524. 2017. View Article : Google Scholar : PubMed/NCBI
4	Won KI and Spruck C: Triple-negative breast cancer therapy: Current and future perspectives (Review). Int J Oncol. 57:1245–1261. 2020. View Article : Google Scholar : PubMed/NCBI
5	Gradishar WJ, Moran MS and Abraham J: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 4. 2022.Available from:. www.nccn.org
6	Ye L, Jia Y, Ji KE, Saunders AJ, Xue K, Ji J, Mason MD and Jiang WG: Traditional Chinese medicine in prevention and treatment of breast cancer and metastasis. Oncol Lett. 10:1240–1250. 2015. View Article : Google Scholar : PubMed/NCBI
7	Yang Z, Zhang Q, Yu L, Zhu J, Cao Y and Gao X: The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer. J Ethnopharmacol. 264:1132492021. View Article : Google Scholar : PubMed/NCBI
8	Telang NT, Li G, Sepkovic DW, Bradlow HL and Wong GYC: Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor positive clinical breast cancer. Mol Med Rep. 5:22–28. 2012.PubMed/NCBI
9	Telang N, Li G, Katdare M, Sepkovic D, Bradlow L and Wong G: Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function. Oncol Lett. 12:3949–3957. 2016. View Article : Google Scholar : PubMed/NCBI
10	Telang NT, Li G, Katdare M, Sepkovic DW, Bradlow HL and Wong GYC: The nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer. Oncol Lett. 13:2477–2482. 2017. View Article : Google Scholar : PubMed/NCBI
11	Telang NT, Nair HB and Wong GYC: Growth inhibitory efficacy of Cornus officinalis in a cell culture model for triple-negative breast cancer. Oncol Lett. 17:5261–5266. 2019.PubMed/NCBI
12	Telang NT, Nair HB and Wong GYC: Growth inhibitory efficacy of the nutritional herb Psoralia corylifolia in a model of triple-negative breast cancer. Int J Funct Nutr. 2:82021. View Article : Google Scholar
13	Telang NT, Nair HB and Wong GYC: Growth inhibitory efficacy of Chinese herbs in a cellular model for triple-negative breast cancer. Pharmaceuticals (Basel). 14:13182021. View Article : Google Scholar : PubMed/NCBI
14	Telang N, Nair HB and Wong GYC: Anti-proliferative and pro-apoptotic effects of Dipsacus asperoides in a cellular model for triple-negative breast cancer. Arch Breast Cancer. 9:66–75. 2022. View Article : Google Scholar
15	Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark I, Bayani N, Cope JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
16	Subik K, Lee JF, Baxret I, Strzepak T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and Tang P: The expression pattwerns of ER, PR, HER-2, CK 5/6, EGFR, Ki 67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI
17	Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, Huang H, Wang L, James JL, Balko JM, et al: Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 12:62762021. View Article : Google Scholar : PubMed/NCBI
18	Burkhart DL and Sage J: Cellular mechanisms of tumor suppression by the retinoblastoma gene. Nat Rev Cancer. 8:671–682. 2008. View Article : Google Scholar : PubMed/NCBI
19	Chen HZ, Tsai SY and Leone G: Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev Cancer. 9:785–797. 2009. View Article : Google Scholar : PubMed/NCBI
20	Otto T and Sicinski P: Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115. 2017. View Article : Google Scholar : PubMed/NCBI
21	Chang EJ, Lee WJ, Cho SH and Choi SW: Proliferative effects of flavan-3-olsand propelargonidins from rhizomes of Drynaria fortunei on MCF-7 and osteoblastic cells. Arch Pharmacol Res. 26:620–630. 2003. View Article : Google Scholar
22	Wong KC, Pang WY, Wang XL, Mok SK, Lai WP, Chow HK, Leung PC, Yao SX and Wong MS: Drynaria fortunei-derived total flavonoid fraction and isolated compounds exert oestrogen-like protective effects in bone. Br J Nutr. 110:475–485. 2013. View Article : Google Scholar : PubMed/NCBI
23	Huang ST, Chang CC, Pang JH, Huang HS, Chou SC, Kao MC and You HL: Drynaria fortunei promoted angiogenesis associated with modified MMP-2/TMP-2 balance and activation of VEGF ligand/receptors expression. Front Pharmacol. 9:9792018. View Article : Google Scholar : PubMed/NCBI
24	Qiao X, Lin XH, Liang YH, Dong J, Guo DA and Ye M: Comprehensive chemical analysis of the rhizomes of Drynaria fortune by orthogonal pre-separation and liquid chromatography mass spectrometry. Planta Med. 80:330–336. 2014. View Article : Google Scholar : PubMed/NCBI
25	Xie L, Zhao S, Zhang X, Huang W, Qiao L, Zhan D, Ma C, Gong W, Dang H and Lu H: Wenshengyang recipe treats infertility through hormonal regulation and inflammatory responses revealed by transcriptome analysis and network pharmacology. Front Pharmacol. 13:9175442022. View Article : Google Scholar : PubMed/NCBI
26	Telang NT: Stem cell models for breast and colon cancer: Experimental approach for drug discovery. Int J Mol Sci. 23:92232022. View Article : Google Scholar : PubMed/NCBI
27	Telang NT: Natural products as drug candidates for breast cancer (Review). Oncol Lett. 26:3492023. View Article : Google Scholar : PubMed/NCBI
28	Hannen R and Bartsch JW: Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. FEBS Lett. 592:2023–2031. 2018. View Article : Google Scholar : PubMed/NCBI
29	Kumar VE, Nambiar R, De Souza C, Nguyen A, Chien J and Lam KS: Targeting epigenetic modifiers of tumor plasticity and cancer stem cell behavior. Cells. 11:14032022. View Article : Google Scholar : PubMed/NCBI
30	Gooding AJ and Scheiman WP: Epithelial-mesenchymal transition programs and cancer stem cell phenotypes Mediators of breast cancer therapy resistance. Mol Cancer Res. 18:1257–1270. 2020. View Article : Google Scholar : PubMed/NCBI
31	Ganeshan K and Xu B: Telomerase inhibitors from natural products and their anticancer potential. Int J Mol Sci. 19:132017. View Article : Google Scholar
32	Liskova A, Kubatka P, Samec M, Zubor P, Mlyneck M, Bielik T, Samuel SM, Zulli A, Kwon TK and Busselberg D: Dietary phytochemicals targeting cancer stem cells. Molecules. 24:8992019. View Article : Google Scholar : PubMed/NCBI
33	Jin W: Role of JAK/STAT 3 signaling in the regulation of metastasis, the transition of cancer stem cells and chemo-resistance of cancer by epithelial-mesenchymal transition. Cells. 9:2172020. View Article : Google Scholar : PubMed/NCBI